Working with a patient advocate on a document
Working with patient advocates requires time to find suitable contributors, explain the task, agree terms and build trust. Their input is strongest when the relationship makes room for different experiences, supports participation and gives patients a clear role in shaping the work.
Finding contributors
National or umbrella patient organisations are an obvious starting point. Disease-specific organisations and community advisory boards, groups of volunteer patients offering expertise to clinical-research sponsors, provide further routes. EUPATI Connect includes independent, unaffiliated advocates as well as organisation members; a pharmaceutical client may already be connected through an industry partnership. The partnership network includes industry, patient organisations, academia, nonprofits and national platforms.
Social media and awareness days or months can help identify advocates who are active online. One search around Glioblastoma Awareness Day found an adult survivor advocating in an area where such advocates were rare. Searching beyond English and speaking another language can extend access to advocates.
Patient associations can introduce individual contributors through review boards of people willing to participate in information projects. In Karger's Fast Facts for Patients projects, the editor contacted associations before writing, discussed collaboration and asked them to recruit focus-group patients. Participants sometimes knew each other from earlier work, but more often did not. Covering many conditions without permanent patient-reviewer or clinical-adviser boards required new relationships for each project, built entirely online.
Freelance writers' flexibility, accessibility and occasional freedom to follow intellectual or scientific interests can make them suitable partners for patient associations. Possible collaborations include awareness campaigns, website updates and scientific meetings.
Compensation and conflicts of interest
Client compensation policies and national guidance should be checked before approaching advocates because the expected input and available remuneration can affect participation. Remuneration remained a tension limiting meaningful, efficient interaction in July 2024, prompting calls for global consistency and transparency. Patient Focused Medicines Development was co-creating a process with stakeholders and decision makers to harmonise earlier work and establish a trusted process for fair remuneration for pharmaceutical-industry engagement.
Industry funding of patient organisations also raises conflicts of interest. PARADIGM guidance covers definitions and types of interest, recommendations and mitigation, vulnerable populations, and example activities with different restrictions.
Scope, availability and consent
Requests should allow realistic lead time: well-known advocates often have full schedules and cannot be expected to accept urgent last-minute work, while newer, less well-known advocates may be more available. Preferred communication methods should be discussed rather than assumed. Checking patient-community discussions can reveal sensitive language and imagery; the aim is empathy for people who have worked persistently for change.
Patients and associations need to understand the request, the writer needs to understand the extent of their involvement, and both need a record of the agreement. Essentials can be set out in an introductory email, details developed in meetings and a simple agreement or patient consent document signed.
In the Fast Facts process, consent before the focus group covered participation, the right to withdraw before publication, the preferred method of receiving compensation and permission to use the person's name. Patients also agreed to review the written booklet; early input may give them a sense of ownership, and their reviews were observed to be careful and considered. A booklet took approximately eight to ten months, with the focus group held before writing to understand life with the disease and what patients needed from the resource. An assigned freelance writer joined the group too.
Trust in an online relationship
A sponsor's introduction can help establish trust, but does not guarantee it. In one information project, agreement took months and tense, unproductive meetings left writing unstarted after another two months. The association distrusted both publisher and sponsor after a previous sponsor-funded project had left it feeling disrespected and misunderstood; asking about that experience began a healthier relationship.
Back-to-back online meetings can leave little room for the small talk that helps people learn each other's roles, locations and relationship to the condition. Some advocacy-group staff are patients themselves. Small talk can ease tension and build relationships, although practice varies and cultural differences appear influential. One editor began association calls at least five minutes early and patient meetings ten minutes early, finding that anxious newcomers often joined immediately and informal conversation helped meetings start punctually.
Reputation, online presence, reviews and accreditation can support trust. Associations unfamiliar with an accreditation may need an explanation of its meaning and how the publisher follows good practice, supports health literacy and writes plain language. Such knowledge cannot be assumed: one association had only a superficial understanding of readability and reading age and was initially dismissive of PIF Tick until given further reading.
Facilitating patient discussion
Facilitation combines listening, support and follow-up questions with ensuring that confident speakers do not silence less confident participants. Grief, sadness and anger may arise, and sessions can be emotionally and mentally tiring; one experienced facilitator avoided scheduling two in the same week after trying it once.
Sending possible questions in advance and inviting each participant to choose a couple gives them room to discuss what matters to them. A few guiding questions after informal conversation can be enough for a natural discussion, rather than running the group as an interview. Patients with the same disease can have very different experiences, and their accounts can change a resource's content, wording and tone. A wish to improve others' experience of illness can motivate people to speak to a stranger online; the writer's task is to provide a respectful, warm and trusted setting.
Rare-disease expertise and support
Patient expertise is particularly important where knowledge of a rare disease is scarce, helping define research needs, strategies and patient-relevant outcomes. Patient information can also be scarce in these conditions. Guidance such as the EURORDIS Charter for Clinical Trials recommends informing patient organisations about all aspects of a protocol before collaboration and publishing results even when negative or inconclusive. Documents should support both trained and untrained contributors, since lived experience does not imply drug-development training; EURORDIS Open Academy offered summer and winter schools with training and mentorship in the 2018 account.
Involving advocacy groups in trial-document preparation, including consent documents, may help foster trust between pharmaceutical companies and patients.